MedTrace Logo

Transcranial Magnetic Stimulation for Treatment of Methamphetamine Dependence

NCT03827785 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2021-09-16

No results posted yet for this study

Summary

Repetitive transcranial magnetic stimulation (rTMS) was used to treat methamphetamine (MA) addiction in previous studies, while the evidence-based protocols still required. The aim of this research is to evaluating the effectiveness and safety of rTMS treatment in improving the days of abstinence maintenance. In addition, treatment effect on cognitive impairment, psychological craving and depression are also evaluated during the study.

Conditions

  • Methamphetamine-dependence

Interventions

DEVICE

rTMS treatment group

For rTMS treatment, we will stimulate the dorsal lateral prefrontal cortex of each patients using the iTBS pattern everyday. Treatment will lasted for 30 days.

DEVICE

sham rTMS treatment group

For sham rTMS treatment, we will stimulate the dorsal lateral prefrontal cortex of each patients using the sham iTBS pattern and sham coil everyday for 30 minutes. Treatment will lasted for 30 days.

Sponsors & Collaborators

  • Wuxi Mental Health Center, Jiangsu Provence, China

    collaborator UNKNOWN

  • Suzhou Guangji Hospital, Jiangsu Provence, China

    collaborator UNKNOWN

  • Wuhan Mental Health Center, Hubei Provence, China

    collaborator UNKNOWN

  • Yunnan Institute For Drug Abuse

    collaborator UNKNOWN

  • Shanghai Mental Health Center

    lead OTHER

Principal Investigators

  • Haifeng Jiang · Shanghai Mental Health Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-02-01
Primary Completion
2020-09-01
Completion
2020-12-12

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03827785 on ClinicalTrials.gov